Cargando…
Response to Neoadjuvant Therapy and Prognosis in Patients with Resectable Pancreatic Cancer: A Propensity Score Matching Analysis
BACKGROUND/AIMS: Controversy regarding the effectiveness of neoadjuvant therapy for resectable pancreatic ductal adenocarcinoma (PDAC) still exists. Here, we aimed to identify the potential benefits of neoadjuvant therapy followed by surgery for resectable PDAC. METHODS: We reviewed radiologically r...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Editorial Office of Gut and Liver
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8761915/ https://www.ncbi.nlm.nih.gov/pubmed/34140428 http://dx.doi.org/10.5009/gnl20301 |
_version_ | 1784633642074505216 |
---|---|
author | Yoon, Min Sung Lee, Hee Seung Kang, Chang Moo Lee, Woo Jung Keum, Jiyoung Sung, Min Je Kim, Seung-seob Park, Mi-Suk Jo, Jung Hyun Chung, Moon Jae Park, Jeong Youp Park, Seung Woo Song, Si Young Hwang, Ho Kyoung Bang, Seungmin |
author_facet | Yoon, Min Sung Lee, Hee Seung Kang, Chang Moo Lee, Woo Jung Keum, Jiyoung Sung, Min Je Kim, Seung-seob Park, Mi-Suk Jo, Jung Hyun Chung, Moon Jae Park, Jeong Youp Park, Seung Woo Song, Si Young Hwang, Ho Kyoung Bang, Seungmin |
author_sort | Yoon, Min Sung |
collection | PubMed |
description | BACKGROUND/AIMS: Controversy regarding the effectiveness of neoadjuvant therapy for resectable pancreatic ductal adenocarcinoma (PDAC) still exists. Here, we aimed to identify the potential benefits of neoadjuvant therapy followed by surgery for resectable PDAC. METHODS: We reviewed radiologically resectable PDAC patients who received resection with curative intent at a tertiary hospital in South Korea between January 2012 and August 2019. A total of 202 patients underwent curative resection for resectable PDAC 167 underwent surgical resection first during this period, and 35 received neoadjuvant chemotherapy/chemoradiation therapy followed by surgery. Resectable PDAC patients were subdivided, and 13 propensity score matching (PSM) was performed to reduce selection bias. RESULTS: Compared with the group that received surgery first, the group that received neoadjuvant treatment followed by surgery had significantly smaller tumors (22.0 mm vs 27.0 mm, p=0.004), a smaller proportion of patients with postoperative pathologic T stage (p=0.026), a smaller proportion of patients with lymphovascular invasion (20.0% vs 40.7%, p=0.022), and a larger proportion of patients with negative resection margins (74.3% vs 51.5%, p=0.049). After PSM, the group that received neoadjuvant therapy had a significantly longer progression-free survival than those in the group that underwent surgery first (29.6 months vs 15.1 months, p=0.002). Overall survival was not significantly different between the two groups after PSM analysis. CONCLUSIONS: We observed significantly better surgical outcomes and progression-free survival with the addition of neoadjuvant therapy to the management of resectable PDAC. However, despite PSM, there was still selection bias due to the use of different regimens between the groups receiving surgery first and neoadjuvant therapy. Large homogeneous samples are needed in the future prospective studies. |
format | Online Article Text |
id | pubmed-8761915 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Editorial Office of Gut and Liver |
record_format | MEDLINE/PubMed |
spelling | pubmed-87619152022-01-25 Response to Neoadjuvant Therapy and Prognosis in Patients with Resectable Pancreatic Cancer: A Propensity Score Matching Analysis Yoon, Min Sung Lee, Hee Seung Kang, Chang Moo Lee, Woo Jung Keum, Jiyoung Sung, Min Je Kim, Seung-seob Park, Mi-Suk Jo, Jung Hyun Chung, Moon Jae Park, Jeong Youp Park, Seung Woo Song, Si Young Hwang, Ho Kyoung Bang, Seungmin Gut Liver Original Article BACKGROUND/AIMS: Controversy regarding the effectiveness of neoadjuvant therapy for resectable pancreatic ductal adenocarcinoma (PDAC) still exists. Here, we aimed to identify the potential benefits of neoadjuvant therapy followed by surgery for resectable PDAC. METHODS: We reviewed radiologically resectable PDAC patients who received resection with curative intent at a tertiary hospital in South Korea between January 2012 and August 2019. A total of 202 patients underwent curative resection for resectable PDAC 167 underwent surgical resection first during this period, and 35 received neoadjuvant chemotherapy/chemoradiation therapy followed by surgery. Resectable PDAC patients were subdivided, and 13 propensity score matching (PSM) was performed to reduce selection bias. RESULTS: Compared with the group that received surgery first, the group that received neoadjuvant treatment followed by surgery had significantly smaller tumors (22.0 mm vs 27.0 mm, p=0.004), a smaller proportion of patients with postoperative pathologic T stage (p=0.026), a smaller proportion of patients with lymphovascular invasion (20.0% vs 40.7%, p=0.022), and a larger proportion of patients with negative resection margins (74.3% vs 51.5%, p=0.049). After PSM, the group that received neoadjuvant therapy had a significantly longer progression-free survival than those in the group that underwent surgery first (29.6 months vs 15.1 months, p=0.002). Overall survival was not significantly different between the two groups after PSM analysis. CONCLUSIONS: We observed significantly better surgical outcomes and progression-free survival with the addition of neoadjuvant therapy to the management of resectable PDAC. However, despite PSM, there was still selection bias due to the use of different regimens between the groups receiving surgery first and neoadjuvant therapy. Large homogeneous samples are needed in the future prospective studies. Editorial Office of Gut and Liver 2022-01-15 2021-06-22 /pmc/articles/PMC8761915/ /pubmed/34140428 http://dx.doi.org/10.5009/gnl20301 Text en Copyright © Gut and Liver. https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Yoon, Min Sung Lee, Hee Seung Kang, Chang Moo Lee, Woo Jung Keum, Jiyoung Sung, Min Je Kim, Seung-seob Park, Mi-Suk Jo, Jung Hyun Chung, Moon Jae Park, Jeong Youp Park, Seung Woo Song, Si Young Hwang, Ho Kyoung Bang, Seungmin Response to Neoadjuvant Therapy and Prognosis in Patients with Resectable Pancreatic Cancer: A Propensity Score Matching Analysis |
title | Response to Neoadjuvant Therapy and Prognosis in Patients with Resectable Pancreatic Cancer: A Propensity Score Matching Analysis |
title_full | Response to Neoadjuvant Therapy and Prognosis in Patients with Resectable Pancreatic Cancer: A Propensity Score Matching Analysis |
title_fullStr | Response to Neoadjuvant Therapy and Prognosis in Patients with Resectable Pancreatic Cancer: A Propensity Score Matching Analysis |
title_full_unstemmed | Response to Neoadjuvant Therapy and Prognosis in Patients with Resectable Pancreatic Cancer: A Propensity Score Matching Analysis |
title_short | Response to Neoadjuvant Therapy and Prognosis in Patients with Resectable Pancreatic Cancer: A Propensity Score Matching Analysis |
title_sort | response to neoadjuvant therapy and prognosis in patients with resectable pancreatic cancer: a propensity score matching analysis |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8761915/ https://www.ncbi.nlm.nih.gov/pubmed/34140428 http://dx.doi.org/10.5009/gnl20301 |
work_keys_str_mv | AT yoonminsung responsetoneoadjuvanttherapyandprognosisinpatientswithresectablepancreaticcancerapropensityscorematchinganalysis AT leeheeseung responsetoneoadjuvanttherapyandprognosisinpatientswithresectablepancreaticcancerapropensityscorematchinganalysis AT kangchangmoo responsetoneoadjuvanttherapyandprognosisinpatientswithresectablepancreaticcancerapropensityscorematchinganalysis AT leewoojung responsetoneoadjuvanttherapyandprognosisinpatientswithresectablepancreaticcancerapropensityscorematchinganalysis AT keumjiyoung responsetoneoadjuvanttherapyandprognosisinpatientswithresectablepancreaticcancerapropensityscorematchinganalysis AT sungminje responsetoneoadjuvanttherapyandprognosisinpatientswithresectablepancreaticcancerapropensityscorematchinganalysis AT kimseungseob responsetoneoadjuvanttherapyandprognosisinpatientswithresectablepancreaticcancerapropensityscorematchinganalysis AT parkmisuk responsetoneoadjuvanttherapyandprognosisinpatientswithresectablepancreaticcancerapropensityscorematchinganalysis AT jojunghyun responsetoneoadjuvanttherapyandprognosisinpatientswithresectablepancreaticcancerapropensityscorematchinganalysis AT chungmoonjae responsetoneoadjuvanttherapyandprognosisinpatientswithresectablepancreaticcancerapropensityscorematchinganalysis AT parkjeongyoup responsetoneoadjuvanttherapyandprognosisinpatientswithresectablepancreaticcancerapropensityscorematchinganalysis AT parkseungwoo responsetoneoadjuvanttherapyandprognosisinpatientswithresectablepancreaticcancerapropensityscorematchinganalysis AT songsiyoung responsetoneoadjuvanttherapyandprognosisinpatientswithresectablepancreaticcancerapropensityscorematchinganalysis AT hwanghokyoung responsetoneoadjuvanttherapyandprognosisinpatientswithresectablepancreaticcancerapropensityscorematchinganalysis AT bangseungmin responsetoneoadjuvanttherapyandprognosisinpatientswithresectablepancreaticcancerapropensityscorematchinganalysis |